Category: Covid-19 Vaccine

For Immediate ReleaseMarch 25, 2022

The United States Government today, announced plans to provide $1.5 million in urgent COVID-19 assistance through the United States Agency for International Development (USAID) for countries including Antigua and Barbuda, Dominica, Grenada, Barbados, St. Kitts and Nevis, Saint Lucia, St. Vincent and the Grenadines, The Bahamas, Guyana, Suriname, and Trinidad and Tobago.

This assistance will be focused on helping countries with vaccine deployment and readiness, and includes efforts to address vaccine hesitancy and combat vaccine mis- and dis-information. The additional support will assist with community vaccination campaigns and engagement activities, strengthen the cold chain environment, train healthcare workers, and develop regional and country specific campaigns to increase vaccine uptake.

Activities will be implemented through local, regional, and international organizations such as the local Ministries of Health, local non-governmental organizations, the Caribbean Public Health Agency (CARPHA), the Pan American Health Organization (PAHO), UNICEF, and the USAID Country Health Information Systems and Data Use (CHISU) project implemented by JSI Research and Training Institute, Inc.

U.S. Ambassador to Barbados, the Eastern Caribbean and the Organization of Eastern Caribbean States, Linda Taglialatela, remarked, Through this funding, the United States is extending a helping hand to countries to aid in health and economic recovery from the devastation of COVID-19.

USAID Regional Representative for the Eastern and Southern Caribbean, Clinton. D. White, noted, The funding will fill key gaps to accelerate COVID-19 vaccine uptake, and strengthen countries preparedness for future pandemic threats.

This additional assistance builds on previous COVID-19 support provided to Caribbean countries. USAID has provided nearly $63 million in COVID-19 assistance to the Caribbean to address the health, humanitarian, and economic impacts of COVID-19.This includes more than $7 million specifically for the Eastern and Southern Caribbean region since the beginning of the pandemic.

USAIDs COVID-19 assistance to Caribbean countries has allowed for the procurement of more than 7,000 test kits and more than 3,000 pieces of protective gear for health workers. Through the United States Governments assistance, these countries have also received ambulances and vehicles for patient transport. In addition, communications campaigns to promote health and safety have reached more than 1.2 million people. Finally, the funds have facilitated the provision of psychosocial support for more than 95,000 parents and caregivers, as well as assisted with the installation of more than 300 handwashing stations across the Caribbean.

Diseases know no borders. The United States Government is committed to partnering with our Caribbean neighbors, partners, and friends to end the COVID-19 pandemic, save lives, and stop the threat of dangerous new variants.

-End-

By U.S. Embassy Bridgetown | 25 March, 2022 | Topics: News, Press Releases

Read more:

United States Plans to Provide Further $1.5 Million for Urgent COVID-19 Vaccination Assistance in Caribbean Countries - US Embassy in Barbados

FILE PHOTO: 89-year-old Yodit Ben Ari receives a fourth dose of the coronavirus disease (COVID-19) vaccine following a vaccination party after Israel approved a second booster shot for the immunocompromised, people over 60 years and medical staff in a retirement home in Netanya, Israel January 5, 2022. REUTERS/Ammar Awad

See more here:

Senior citizens receive a fourth dose of the COVID-19 vaccine at a vaccination party in Netanya - Colorado Springs Gazette

File photo of a vaccination clinic in Fulton March 2021 - Judy Grandy, director of environmental health for the Oswego County Health Department, is pictured talking with a patient. Photo courtesy of Sonia Robinson.

OSWEGO COUNTY The Oswego County Health Department continues to offer COVID-19 vaccines for county residents at weekly vaccination clinics, with Wednesday walk-in clinics starting April 6.

Following more than a year of holding vaccination clinics in locations throughout the county, the health department is transitioning to include the COVID-19 vaccine as part of weekly vaccine clinics offered at the Nick Sterio Public Health Clinic in Oswego. Anyone seeking the COVID-19 vaccine, or other general immunizations, can call the Oswego County Health Department at 315-349-3547 or schedule a COVID-19 vaccine online.

COVID-19 vaccines are also available at medical provider offices and local pharmacies.

To view a list of upcoming clinics and schedule an appointment, go to health.oswegocounty.com/vaccines and scroll down to the calendar to click on the date and dose needed.

The following upcoming clinics are scheduled:

Tuesday, March 2912:30-3:30 p.m. Nick Sterio Public Health Clinic, 70 Bunner St., OswegoGeneral childhood and adult immunizations, including COVID-19 vaccines. Appointments are required.

Wednesday, March 303:30-4:30 p.m. Nick Sterio Public Health Clinic, 70 Bunner St., OswegoAnyone aged 12 and older can receive a first, second or booster dose of the Pfizer-BioNTech vaccine. Anyone aged 18 and older can receive a Janssen/Johnson & Johnson vaccine or booster dose. Appointments are required.

Tuesday, April 512:30-3:30 p.m. Nick Sterio Public Health Clinic, 70 Bunner St., OswegoGeneral childhood and adult immunizations, including COVID-19 vaccines. Appointments are required.

Starting April 6, the Oswego County Health Department will hold walk-in clinics each Wednesday at the Nick Sterio Public Health Clinic, from 9-11 a.m. and 1-3 p.m. Attendees aged 5 and older can receive age-appropriate recommended doses of the Pfizer-BioNTech vaccine, and anyone aged 18 and older can receive recommended doses of the Modern or Janssen/Johnson & Johnson vaccines.

At-home COVID-19 test kits will be distributed to individuals who are vaccinated at upcoming clinics. Test kits will be distributed while supplies last.

Face masks are required at all health care settings regulated by the state Department of Health, including the Oswego County Health Department and any vaccination site.

For more information, go to the Oswego County Health Departments COVID-19 page at health.oswegocounty.com/covid-19 or call the COVID-19 hotline at 315-349-3330.

Residents should contact their medical providers directly for personal medical advice related to COVID-19 vaccinations, booster shots or treatments.

Under New York State Public Health Law, the Oswego County Health Department is the local public health authority regarding the COVID-19 pandemic response within the County of Oswego. The Oswego County Health Department works closely with New York State Department of Health regarding COVID-19 monitoring, response and reporting.

Like Loading...

Related

Read more from the original source:

COVID-19 Vaccine Continues To Be Offered At Clinics This Week - Oswego Daily News

The Queens Health System will be offering its last COVID-19 vaccines at The Queens Medical Center-West Oahu this Saturday.

After that, Queens will be moving COVID-19 vaccination operations in West Oahu to EmPower Health at 91-6390 Kapolei Parkway at the corner of Kapolei Parkway and Keoneula Boulevard, which will begin offering vaccines on Tuesday.

Vaccinations at EmPower, a primary care center, will be available from 11:30 a.m. to 8 p.m. weekdays.

I would like to thank our dedicated team of caregivers at Queens-West who stepped up to provide vaccinations for our West Oahu community, said Jason Chang, Queens executive vice president and chief operating officer, in a news release. Their monumental efforts helped keep our community safe from COVID-19.

Queens has administered more than 405,000 doses of COVID-19 vaccines since December 220, including nearly 90,000 at the Queens-West vaccination clinic, which opened in March 2021.

Queens said it will continue efforts to reach underserved communities through mobile vaccination clinics. Queens also offers COVID-19 vaccines at the Queens Physicians Office Building II, Suite 203, daily (6:45 a.m. 6:20 p.m.) except Sundays, and at Queens Island Urgent Care-Kahala, 1215 Hunakai St, daily (8 a.m.-7:45 p.m.) except Sundays.

Both clinics offer the Pfizer vaccine for those ages 5 and older, and the Moderna vaccine for anyone 18 and older.

Appointments are available at covid.queens.org/vaccine or by calling 808-691-2222. Walk-ins are also accepted.

See more here:

Queens-West moving COVID-19 vaccinations to EmPower Health in Kapolei - Honolulu Star-Advertiser

Will babies and young kids get COVID-19 vaccines before a BA.2 surge? Here's what health experts say.  USA TODAY

Originally posted here:

Will babies and young kids get COVID-19 vaccines before a BA.2 surge? Here's what health experts say. - USA TODAY

GAITHERSBURG, Md., March 25, 2022 /PRNewswire/ --Novavax Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine, is included in two trials now underway to evaluate its vaccine's safety, immunogenicity, and reactogenicity as a booster amidst the ongoing COVID-19 pandemic. Both studies have initiated participant enrollment and will help to extend knowledge of how a range of vaccines, including Novavax' COVID-19 vaccine, can be used as boosters following primary immunization.

"Additional COVID-19 booster studies are important to support vaccine choice for individuals, healthcare providers, and public health authorities," said Filip Dubovsky, M.D., Chief Medical Officer, Novavax. "Our COVID-19 vaccine has already been recommended by multiple national policy bodies for both primary vaccination and booster settings in individuals 18 years of age and older. We look forward to adding to this body of evidence to support the expanded use of our protein-based vaccine."

Novavax is participating in an ongoing Phase 1/2 trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) to assess homologous and heterologous boosting regimens in participants who received a primary series of a COVID-19 vaccine which has received full approval or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Participants will be given a third dose (> 12 weeks later) of either NVX-CoV2373 or one of the three COVID-19 vaccines that have already received EUA or full authorization from the FDA. The study is enrolling approximately 1,130 healthy individuals aged 18 years or older, about 180 of whom will receive NVX-CoV2373 as a heterologous booster. The trial is being conducted at approximately 10 clinical research sites and its primary objectives are to evaluate safety, reactogenicity, and immunogenicity of delayed heterologous or homologous vaccine doses after EUA dosed vaccines. Participants will be followed for 12 months, with topline results expected later this year and full results expected in 2023.

Novavax' COVID-19 vaccine is also being evaluated in an observer-blinded Phase 3 study in the United Arab Emirates (UAE) to assess homologous versus heterologous boosting of participants who have already been immunized with Sinopharm's COVID-19 vaccine. The safety and immunogenicity of a single booster dose of Novavax' COVID-19 vaccine in adults previously vaccinated with Sinopharm's COVID-19 vaccine will be evaluated. The study is enrolling approximately 1,000 participants aged 18 years or older at two centers in Abu Dhabi with the goal of providing data to support boosting with NVX-CoV2373 in the large number of individuals who have been vaccinated with inactivated vaccines globally. Participants will be followed for six months, with full results expected during the fourth quarter of 2022. The Ministry of Health and Prevention approved NVX-CoV2373 for emergency use in the UAE in December.

For more information about the NIAID-sponsored study, readhereonclinicaltrials.gov. For more information about the study in the UAE, read here onclinicaltrials.gov. NVX-CoV2373 has not yet been authorized for use by the FDA, nor has it received heterologous or homologous booster approval in all the countries where it's been authorized.

Important Safety Information

About NVX-CoV2373

NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2- 8 Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.

Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India (SII), the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain.

About the NVX-CoV2373 Phase 3 trials

NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials.

PREVENT-19, a trial in the U.S. andMexicothat enrolled almost 30,000 participants aged 18 years and older, achieved 90.4% efficacy overall. It was designed as a 2:1 randomized, placebo-controlled, observer-blinded study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in theNew England Journal of Medicine(NEJM).

A trial conducted in the U.K. with 14,039 participants aged 18 years and older was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least 7 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published inNEJM.

About Matrix-M Adjuvant

Novavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu, its quadrivalent influenza investigational vaccine candidate. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visitwww.novavax.com and connect with us on Twitter, LinkedIn, Instagram and Facebook.

Forward-Looking Statements

Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373 and NanoFlu, its COVID-seasonal influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax' plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax' global supply chain, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, and the efficacy, safety and intended utilization of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at http://www.sec.gov and http://www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

InvestorsNovavax, Inc.Erika Schultz | 240-268-2022ir@novavax.com

Solebury TroutAlexandra Roy | 617-221-9197aroy@soleburytrout.com

MediaAli Chartan | 240-720-7804Laura Keenan Lindsey | 202-709-7521media@novavax.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-announces-participation-in-two-booster-studies-using-its-covid-19-vaccine-301510755.html

SOURCE Novavax, Inc.

Read the rest here:

Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine - BioSpace

As of March 17, 2022, the U.S. has provided funding and in-kind support for the global COVID-19 response, including delivering half a billion donated COVID-19 vaccine doses to more than 110 countries, with more donated doses to come. These efforts have been part of the Biden administrations plan to usher in an end to the pandemic emergency, reduce the impact of COVID globally, and help reduce the chance of new, more-transmissible variants from emerging. In November 2021, polling from the KFF COVID-19 Vaccine Monitor found the public was generally supportive of the U.S. helping to provide vaccines to other countries, especially when people were informed that the U.S. has enough of its own vaccine supply.

The latest KFF COVID-19 Vaccine Monitor (conducted February 9-21, 2022) continues to find that the public is largely supportive of the U.S. role in global vaccine distribution, as well as other response efforts including the distribution of masks and COVID-19 rapid tests. A plurality of adults think the U.S. is doing about the right amount to make sure people in other countries have access to COVID-19 vaccines (42%) or control the spread of COVID-19 in other countries by providing masks by providing masks or rapid tests (42%). Smaller shares say the U.S. is doing too much or not enough on both of these efforts. Around a quarter say the U.S. isnt doing enough to make sure people in other countries have access to vaccines (28%) or to control the spread of COVID-19 in other countries (27%). About one in five say the U.S. is doing too much on both of these fronts.

Overall, the public thinks the Biden administration could do more to combat COVID-19 misinformation in other countries. A previous KFF report found widespread belief in COVID-19 misinformation in the U.S. and the WHO has said COVID misinformation was a major factor fueling the pandemic throughout the world. Around four in ten (41%) say the U.S. isnt doing enough to combat misinformation about COVID-19 in other countries, while 28% of adults say the U.S. is doing about the right amount and 18% say were doing too much.

There are strong partisan differences in views of U.S. efforts to combat COVID-19 overseas. Overall, Democrats are more likely than Republicans to say the U.S. isnt doing enough on any of the global COVID-19 response areas asked about in the survey, while Republicans are more likely to say the U.S. is doing too much. More than one-third of Democrats (37%) say the U.S. is not doing enough to make sure people in other countries have access to COVID-19 vaccines, while a similar share of Republicans (36%) say the U.S. is doing too much on this effort. Similarly, a majority of Democrats say the U.S. is doing about the right amount to control the spread of COVID-19 in other countries by providing masks or rapid tests (55%), while another third say the country isnt doing enough (32%). Less than one in ten Democrats say the U.S. is doing too much (7%). This is compared to nearly half of Republicans (45%) who say the U.S. is doing too much while one-third of Republicans (32%) think the U.S. is doing the right amount, and 16% say were not doing enough.

The partisan divide is somewhat smaller when it comes to the U.S. role in combatting misinformation worldwide. Around half of Democrats say the U.S. isnt doing enough to combat the spread of COVID-19 misinformation in other countries (46%), as do 47% of independents and 30% of Republicans. Yet, one-third of Republicans say the U.S. is doing too much to combat misinformation.

The rest is here:

KFF COVID-19 Vaccine Monitor: Views on the US Role In Global COVID-19 Response - Kaiser Family Foundation

Mar 23, 2022

Adrian Wojnarowski

Jeff Passan

New York Mayor Eric Adams will lift the city's COVID-19 vaccine mandate on athletes Thursday, paving the way for Brooklyn Nets star Kyrie Irving to play at the Barclays Center on Sunday and for unvaccinated New York Yankees and Mets players to play in their April home openers, sources familiar with the situation told ESPN on Wednesday.

The rollback of the mandate that has applied to all private businesses in the city would cover professional athletes and performers. It would come on the heels of discussions that had given hope to NBA and MLB teams that the long-awaited move would come to fruition.

Adams, who was sworn in Jan. 1 and has eased the city's COVID-19 policies since, said Tuesday: "Baseball, basketball, businesses -- they have to wait until that layer [of progress] comes."

The wait is not expected to be much longer. The Nets, currently in eighth place in the Eastern Conference and subject to the play-in tournament that begins April 12, would get back Irving, who has been kept out of their 35 home games this season. Irving turned 30 on Wednesday and is averaging 27.7 points in 19 games this season.

His absence has dominated headlines about the mandate, though the approach of Opening Day -- the Yankees' home opener is April 7 and the Mets' April 15 -- ratcheted up pressure, with multiple unvaccinated players on both teams.

Because MLB has the lowest vaccination rate of the four major men's professional sports, baseball officials were working with the mayor's office, according to sources, to push for updates to the mandate. Unvaccinated players on road teams have been allowed to play against the Nets and New York Knicks, and would have been eligible to participate against the Yankees and Mets as well.

Adams' announcement Thursday will take place at 11:30 a.m. ET at Citi Field.

Unvaccinated baseball players are expected to miss their teams' games against the Toronto Blue Jays -- and the salary and service time that come with them -- after the league and union agreed that Canadian entry rules would preclude them from playing there. The Yankees play 10 games in Toronto this season.

Before the expected update to the mandate, unvaccinated Yankees and Mets were not "permitted to enter NYC Club facilities," which include "the clubhouse, training rooms, weight rooms, hitting cages, and outdoor playing field areas," according to a memo from the MLB Players Association earlier this week that was obtained by ESPN.

During a COVID-19 outbreak on the Nets in January, Irving stood firm in his decision not to receive the vaccine, telling reporters: "In terms of where I am with my life outside of this, I stay rooted in my decision. And that's just what it is."

The rollback of former Mayor Bill de Blasio's policies by Adams has included an April 4 lifting of the mask mandate for children in day care. While he did not commit to further changes, Adams hinted Tuesday at amendments to the policy that would soon come.

"We're going to do it in the right way," Adams said Tuesday. "We're going to follow the science ... we're going to make the right decision. And in New York, no matter what you do, this is 8.8 million people and 30 million opinions, so you're never going to satisfy New Yorkers, so you must go with the logic, your heart and the science."

Here is the original post:

Sources: New York City COVID-19 vaccine mandate for athletes to be lifted Thursday - ESPN

BOISE, Idaho Treefort 10 organizers will not require the COVID-19 vaccine or proof of a negative test to attend, but people looking to get the vaccine will be to do so through the event's Rock the Shot program.

Treefort attendees can get the vaccine for free through a partnership with Idaho's largest private ambulance company Injury Care Emergency Medical Services (ICEMS).

"We bring medicine to people to can't get to the hospital, right, and so it was kinda a natural fit for us to try to bring vaccines out to people who can't get in," said Dr. Richard Radnovich, director of vaccine and screening for ICEMS. "It's really important, I'm really glad to be here. I'm glad to be partnering with TreeFort and I think we have a lot of good that we can do for folks."

Related: Treefort 10 to drop vaccination, negative COVID-19 requirement

For additional incentives to get vaccinated on site, Treefort 10 will offer free drink vouchers and a $25 voucher for event merchandise or tickets at the box office, as well as free Rock the Shot merchandise.

The clinic will operate at 12th Street and Main Street during the following time slots:

Original post:

Treefort offering COVID-19 vaccines through 'Rock the Shot' event - Idaho News 6 Boise Twin Falls

Half of Cancer Patients Lost Neutralizing Antibodies 6 Months After COVID-19 Vaccination  Cancer Therapy Advisor

See the rest here:

Half of Cancer Patients Lost Neutralizing Antibodies 6 Months After COVID-19 Vaccination - Cancer Therapy Advisor